Psychopharmacology

, Volume 112, Issue 2, pp 293–298

Seroquel: electrophysiological profile of a potential atypical antipsychotic

  • Jeffrey M. Goldstein
  • Linda C. Litwin
  • Evelynjean B. Sutton
  • Jeffrey B. Malick
Original Investigations

DOI: 10.1007/BF02244924

Cite this article as:
Goldstein, J.M., Litwin, L.C., Sutton, E.B. et al. Psychopharmacology (1993) 112: 293. doi:10.1007/BF02244924

Abstract

Extracellular single unit recording techniques were employed to compare the effects of seroquel with the reference antipsychotic (AP) agents clozapine and haloperidol in electrophysiological tests that may predict AP activity. Seroquel and clozapine were differentially more active in reversing the inhibitory actions ofd-amphetamine on mesolimbic (A10) than nigrostriatal (A9) dopamine (DA)-containing neurons, whereas haloperidol exhibited the opposite selectivity. In cell population studies, acute treatment with seroquel and clozapine selectively increased the number of spontaneously active A10 DA cells, which was found to correlate with the ability of both these drugs to cause depolarization inactivation (DI) of A10 DA cells following repeated (28 day) administration. This profile of activity was unlike that of haloperidol, which acutely caused a nonselective increase in the number of active A9 and A10 DA cells, associated with the ability of this agent to cause DI of both A9 and A10 DA cells after repeated treatment. Since DI of A10 DA cells may be correlated with AP efficacy whereas DI of A9 DA cells may predict the ability of an AP to cause extrapyramidal side effects (EPS) and tardive dyskinesia (TD), seroquel, like clozapine, may be an atypical AP with a reduced likelihood for producing EPS/TD.

Key words

SeroquelICI 204,636Atypical antipsychoticClozapineHaloperidolMidbrain dopamine neuronsAmphetamine reversalDepolarization inactivation

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Jeffrey M. Goldstein
    • 1
  • Linda C. Litwin
    • 1
  • Evelynjean B. Sutton
    • 1
  • Jeffrey B. Malick
    • 1
  1. 1.Department of Pharmacology ICI Pharmaceuticals GroupICI Americas Inc.WilmingtonUSA